Compassionate Use Pathways: How EBC-46 Could Reach Patients Before Full Approval
Regulatory frameworks for compassionate use and expanded access could allow tigilanol tiglate to reach patients with unmet needs well before Phase III completion.
When Patients Cannot Wait for Full Approval
For patients with aggressive or treatment-resistant cancers, the standard regulatory timeline — often spanning a decade from first-in-human dosing to market authorisation — represents a critical gap between scientific promise and clinical access.[1] Compassionate use and expanded access programmes exist precisely to bridge this gap, offering regulatory mechanisms through which investigational drugs like tigilanol tiglate (EBC-46) can reach patients with serious or life-threatening conditions before completing the full approval process.
As EBC-46 advances through clinical development, understanding these pathways is essential for patients, oncologists, and the research community alike.
FDA Expanded Access: The US Framework
The FDA's expanded access programme, codified under 21 CFR 312 Subpart I, permits the use of investigational drugs outside of clinical trials when three conditions are met: the patient has a serious or immediately life-threatening condition, no comparable or satisfactory alternative therapy exists, and the potential benefit justifies the potential risks.[2]
For tigilanol tiglate, several factors strengthen the case for expanded access eligibility. The compound has already demonstrated a favourable safety profile in completed Phase I human trials[3], and its mechanism of action — localised PKC activation leading to targeted tumour necrosis — offers a fundamentally different approach from systemic chemotherapy.[4]
Three categories of expanded access exist under FDA rules: individual patient access (emergency or non-emergency), intermediate-size patient populations, and treatment protocols for widespread use. Each offers a different scale of pre-approval access, with correspondingly different regulatory requirements and oversight levels.
EMA Compassionate Use: The European Pathway
The European Medicines Agency operates its own compassionate use framework under Article 83 of Regulation (EC) No 726/2004. This allows EU Member States to make investigational medicinal products available to groups of patients with chronically or seriously debilitating diseases who cannot be treated satisfactorily by an authorised product.[5]
The EMA's PRIME (PRIority MEdicines) scheme further accelerates this process for products addressing unmet medical needs. Compounds that receive PRIME designation benefit from enhanced interaction with regulatory authorities, early dialogue on development plans, and accelerated assessment — all of which could compress the timeline between clinical data generation and compassionate use availability.
Why EBC-46 Is Positioned for Early Access
Several characteristics of tigilanol tiglate make it a strong candidate for compassionate use pathways:
- Localised administration: Intratumoral injection minimises systemic exposure, reducing the safety concerns that often delay expanded access for systemic oncology drugs.
- Demonstrated veterinary success: Stelfonta's FDA and EMA approvals for canine mast cell tumours have generated extensive real-world safety and efficacy data.[6]
- Mechanism differentiation: EBC-46 works through PKC-mediated vascular disruption and immune activation — a mechanism distinct from existing approved therapies, supporting the "no satisfactory alternative" criterion.[7]
- Unmet need in accessible tumours: Patients with superficial or accessible solid tumours who have exhausted standard options represent a clearly defined population with limited alternatives.
The Bridge Between Research and Relief
Compassionate use is not a shortcut around rigorous science — it is a recognition that some patients face timelines that regulatory processes were not designed to accommodate. For EBC-46, the convergence of promising early clinical data[8], a well-characterised safety profile from veterinary use, and a mechanism targeting accessible tumours creates a compelling case for pre-approval access.
As clinical trials continue to generate data, the regulatory architecture for early patient access is already in place. The question is not whether the pathways exist, but how quickly the clinical evidence will accumulate to activate them — bringing a novel treatment option to patients who need it most.
References
- FDA Orphan Drug Designation programme FDA.gov — Orphan Drug Designation ↗
- Stelfonta FDA veterinary approval FDA.gov — Stelfonta Approval ↗
- Panizza et al. 2019 — Phase I clinical data PubMed ↗
- PKC signalling and cancer biology PubMed ↗
- EMA Stelfonta veterinary authorisation EMA ↗
- Stelfonta FDA approval announcement FDA.gov ↗
- Boyle et al. 2014 — EBC-46 preclinical efficacy PubMed ↗
- Active clinical trials for tigilanol tiglate ClinicalTrials.gov ↗
